Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye

Experimental Hematology

Volumn 30, Issue 10, 2002, Pages 1170-1177

  Li, Ai Hong ^a   Forestier, Erik ^a   Rosenquist, Richard ^b   Roos, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; IMMUNOGLOBULIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE SEQUENCE; HEMATOLOGY; HUMAN; INFANT; MALE; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; ONCOLOGY; POLYMERASE CHAIN REACTION; PRECURSOR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TCR GENE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLUORESCENT DYES; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEOPLASM, RESIDUAL; ORGANIC CHEMICALS; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; RNA, NEOPLASM; TIME FACTORS;

EID: 0036791031     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00892-5     Document Type: Article

References (42)

1. Pui C.H. Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. Curr Opin Hematol. 5:1998;292.
2. Pui C.H. Acute lymphoblastic leukemia. Pediatr Clin North Am. 44:1997;831.
3. Pui C.H. Genetic studies in acute lymphoblastic leukemia. Acta Paediatr Taiwan. 41:2000;303.
4. Forestier E., Johansson B., Gustafsson G.et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia. a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group Br J Haematol. 110:2000;147.
5. Pui C.H. Childhood leukemias. N Engl J Med. 332:1995;1618.
6. Cave H., van der Werff ten Bosch J., Suciu S.et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med. 339:1998;591.
7. Coustan-Smith E., Sancho J., Hancock M.L.et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 96:2000;2691.
8. van Dongen J.J., Seriu T., Panzer-Grumayer E.R.et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 352:1998;1731.
9. Deane M., McCarthy K.P., Wiedemann L.M., Norton J.D. An improved method for detection of B-lymphoid clonality by polymerase chain reaction. Leukemia. 5:1991;726.
10. Potter M.N., Steward C.G., Maitland N.J., Oakhill A. Detection of clonality in childhood B-lineage acute lymphoblastic leukaemia by the polymerase chain reaction. Leukemia. 6:1992;289.
11. Steward C.G., Goulden N.J., Katz F.et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor δ gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood. 83:1994;1355.
12. Li A.H., Rosenquist R., Forestier E.et al. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia. a comparative polymerase chain reaction study using multiple sets of primers Eur J Haematol. 63:1999;211.
13. Coyle L.A., Papaioannou M., Yaxley J.C.et al. Molecular analysis of the leukaemic B cell in adult and childhood acute lymphoblastic leukaemia. Br J Haematol. 94:1996;685.
14. Breit T.M., Wolvers-Tettero I.L., Hahlen K., van Wering E.R., van Dongen J.J. Extensive junctional diversity of gamma delta T-cell receptors expressed by T-cell acute lymphoblastic leukemias. implications for the detection of minimal residual disease Leukemia. 5:1991;1076.
15. Macintyre E., d'Auriol L., Amesland F.et al. Analysis of junctional diversity in the preferential V delta 1-J delta 1 rearrangement of fresh T-acute lymphoblastic leukemia cells by in vitro gene amplification and direct sequencing. Blood. 74:1989;2053.
16. Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia. methodologic advances and clinical significance Blood. 85:1995;1416.
17. van Dongen J.J., Szczepanski T., de Bruijn M.A.et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 2:1996;121.
18. van Dongen J.J., Seriu T., Panzer-Grumayer E.R.et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 352:1998;1731.
19. Kitchingman G.R. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia. 8:1994;395.
20. Cave H., Guidal C., Rohrlich P.et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood. 83:1994;1892.
21. Pongers-Willemse M.J., Verhagen O.J., Tibbe G.J.et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 12:1998;2006.
22. Donovan J.W., Ladetto M., Zou G.et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood. 95:2000;2651.
23. Bruggemann M., Droese J., Bolz I.et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia. 14:2000;1419.
24. Verhagen O.J., Willemse M.J., Breunis W.B.et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 14:2000;1426.
25. Pfitzner T., Engert A., Wittor H.et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia. 14:2000;754.
26. Eckert C., Landt O., Taube T.et al. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 14:2000;316.
27. Bohling S.D., King T.C., Wittwer C.T., Elenitoba-Johnson K.S. Rapid simultaneous amplification and detection of the MBR/JH chromosomal translocation by fluorescence melting curve analysis. Am J Pathol. 154:1999;97.
28. Nakao M., Janssen J.W., Flohr T., Bartram C.R. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res. 60:2000;3281.
29. Gustafsson G., Schmiegelow K., Forestier E.et al. Improving outcome through two decades in childhood ALL in the Nordic countries. the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO) Leukemia. 14:2000;2267.
30. Li A.-H., Rosenquist R., Forestier E., Lindh J., Roos G. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia. implications for minimal residual disease detection Leuk Res. 25:2001;1033.
31. Rosenquist R., Thunberg U., Li A.H.et al. Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia. Eur J Haematol. 63:1999;171.
32. Billadeau D., Blackstadt M., Greipp P.et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction. a technique for sequential quantitation of residual disease Blood. 78:1991;3021.
33. Roberts W.M., Estrov Z., Ouspenskaia M.V., Johnston D.A., McClain K.L., Zipf T.F. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 336:1997;317.
34. Brisco M.J., Sykes P.J., Hughes E.et al. Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia. Leukemia. 15:2001;385.
35. Cave H., van der Werff ten Bosch J., Suciu S.et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med. 339:1998;591.
36. Corradini P., Voena C., Omede P.et al. Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia. 7:1993;1879.
37. Kitchingman G.R. Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood. 81:1993;775.
38. Davi F., Gocke C., Smith S., Sklar J. Lymphocytic progenitor cell origin and clonal evolution of human B-lineage acute lymphoblastic leukemia. Blood. 88:1996;609.
39. Choi Y., Greenberg S.J., Du T.L.et al. Clonal evolution in B-lineage acute lymphoblastic leukemia by contemporaneous VH-VH gene replacements and VH-DJH gene rearrangements. Blood. 87:1996;2506.
40. Coustan-Smith E., Behm F.G., Sanchez J.et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 351:1998;550.
41. Brisco M.J., Condon J., Hughes E.et al. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group. Leukemia. 7:1993;1514.
42. Gruhn B., Hongeng S., Yi H.et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia. 12:1998;675.